國立高雄大學圖資館 |

Language: English

Back

Idiopathic pulmonary fibrosisadvance...

Aoshiba, Kazutetsu.

Idiopathic pulmonary fibrosisadvances in diagnostic tools and disease management /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Idiopathic pulmonary fibrosisedited by Hiroyuki Nakamura, Kazutetsu Aoshiba.
Reminder of title:	advances in diagnostic tools and disease management /
other author:	Nakamura, Hiroyuki.
Published:	Tokyo :Springer Japan :2016.
Description:	x, 259 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
Subject:	Pulmonary fibrosis.
Online resource:	http://dx.doi.org/10.1007/978-4-431-55582-7
ISBN:	9784431555827$q(electronic bk.)

Idiopathic pulmonary fibrosisadvances in diagnostic tools and disease management /
Idiopathic pulmonary fibrosisadvances in diagnostic tools and disease management /[electronic resource] :edited by Hiroyuki Nakamura, Kazutetsu Aoshiba. - Tokyo :Springer Japan :2016. - x, 259 p. :ill., digital ;24 cm.

From epidemiology and pathogenesis to disease management, this book reviews our current understanding of and provides up-to-date information of Idiopathic Pulmonary Fibrosis (IPF) A subtype of Idiopathic Interstitial Pneumonias (IIP), IPF is one of the most elusive and intractable respiratory disease to date and its triggering factors remain unclear. However, new developments such as serum markers that are highly specific to IPF (i.e. KL-6, SP-A, and SP-D), the establishment of systematic diagnostic imaging (HRCT) and accumulated reports of treatment using an antifibrotic agent (pirfenidone) are slowly improving our understanding of the disease. Edited by an established authority in the field and written by experts, this book will be valuable to not only to beginning learners but also to physicians, instructors and researchers whose work involves IIPs. With each chapter exploring critical questions, with unresolved issues and future prospects, the book offers a valuable resource for understanding issues such as the newly proposed entity of interstitial pneumonia with emphysema (combined pulmonary fibrosis and emphysema: CPFE) and the mechanism of how so many IP sufferers develop lung cancer.

ISBN: 9784431555827$q(electronic bk.)

Standard No.: 10.1007/978-4-431-55582-7doiSubjects--Topical Terms:

676426
Pulmonary fibrosis.

LC Class. No.: RC776.F5

Dewey Class. No.: 616.24

Idiopathic pulmonary fibrosisadvances in diagnostic tools and disease management /
LDR:02168nmm a2200301 a 4500 001 481902
003 DE-He213
005 20160727151452.0
006 m d
007 cr nn 008maaau
008 161007s2016 ja s 0 eng d
020 $a 9784431555827$q(electronic bk.)
020 $a 9784431555810$q(paper)
024 7 $a 10.1007/978-4-431-55582-7 $2 doi
035 $a 978-4-431-55582-7
040 $a GP $c GP
041 0 $a eng
050 4 $a RC776.F5
072 7 $a MJL $2 bicssc
072 7 $a MED079000 $2 bisacsh
082 0 4 $a 616.24 $2 23
090 $a RC776.F5 $b I19 2016
245 0 0 $a Idiopathic pulmonary fibrosis $h [electronic resource] : $b advances in diagnostic tools and disease management / $c edited by Hiroyuki Nakamura, Kazutetsu Aoshiba.
260 $a Tokyo : $b Springer Japan : $b Imprint: Springer, $c 2016.
300 $a x, 259 p. : $b ill., digital ; $c 24 cm.
520 $a From epidemiology and pathogenesis to disease management, this book reviews our current understanding of and provides up-to-date information of Idiopathic Pulmonary Fibrosis (IPF) A subtype of Idiopathic Interstitial Pneumonias (IIP), IPF is one of the most elusive and intractable respiratory disease to date and its triggering factors remain unclear. However, new developments such as serum markers that are highly specific to IPF (i.e. KL-6, SP-A, and SP-D), the establishment of systematic diagnostic imaging (HRCT) and accumulated reports of treatment using an antifibrotic agent (pirfenidone) are slowly improving our understanding of the disease. Edited by an established authority in the field and written by experts, this book will be valuable to not only to beginning learners but also to physicians, instructors and researchers whose work involves IIPs. With each chapter exploring critical questions, with unresolved issues and future prospects, the book offers a valuable resource for understanding issues such as the newly proposed entity of interstitial pneumonia with emphysema (combined pulmonary fibrosis and emphysema: CPFE) and the mechanism of how so many IP sufferers develop lung cancer.
650 0 $a Pulmonary fibrosis. $3 676426
650 1 4 $a Medicine & Public Health. $3 273799
650 2 4 $a Pneumology/Respiratory System. $3 274253
650 2 4 $a Cytokines and Growth Factors. $3 379480
700 1 $a Nakamura, Hiroyuki. $3 738248
700 1 $a Aoshiba, Kazutetsu. $3 738249
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-4-431-55582-7
950 $a Medicine (Springer-11650)